micro-community-banner
 
Profile Image
  • Add Media
  • Saved

1yr

The five-day Menopause Society (formerly the North American Menopause Society) 2024 annual meeting took place Sept. 10 to 14 at the Hyatt Regency in Chicago. The agenda was jam-packed with the latest research in understanding and treating menopausal symptoms, with a special focus on artificial intelligence in the women’s health landscape.

Click the link above to find our postconference wrap-up report.

Profile Image
  • Saved

1yr

Taking place at the Hyatt Regency in Chicago, The Menopause Society (formerly North American Menopause Society) is holding its 2024 annual meeting, which spans five days. Attendees are finding it filled with the latest research on understanding and treating menopausal symptoms.

This year’s meeting theme, Humanizing Artificial Intelligence to Improve Midlife Women’s Health, includes actionable advice on the use of artificial intelligence (AI) in clinical practice as well as updates on how AI relates to menopause and midlife women’s health and how future applications may be able to personalize hormone replacement therapy.

Click the link above to find out more about the highlights and programs covered during this years Menopause Society Annual Meeting.

Profile Image
  • Saved

1yr
Background Image DesktopBackground Image Mobile

Knee osteoarthritis (OA) shows early sex-specific differences, evident from childhood. This review highlights anatomical differences, youth sports injuries, and metabolic factors contributing to higher OA risk in females. Addressing these early factors may help mitigate future OA severity in women.

Read More

Profile Image
  • Saved

1yr
Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer - PubMed

Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/38771995/

First-line ribociclib plus ET showed a significant PFS benefit, similar response rates, and better tolerability over combination CT in patients with clinically aggressive HR+/HER2- ABC.

Ribociclib plus endocrine therapy significantly improved progression-free survival compared to combination chemotherapy in clinically aggressive HR+/HER2- advanced breast cancer, with similar response rates and better tolerability.

Profile Image
  • Saved

1yr
Impact of bariatric surgery on premenopausal women's womanliness: A qualitative systematic review and meta-synthesis - PubMed

Impact of bariatric surgery on premenopausal women's womanliness: A qualitative systematic review and meta-synthesis - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/39208194/

Women that have undergone bariatric surgery report several benefits to their health and well-being, although difficulties in adapting mentally to changes in outer appearance need to be managed in order...

Bariatric surgery benefits women by restoring menstruation, improving fertility, and altering fat distribution, but mental adaptation to physical changes remains a challenge.

Profile Image